{
  "ticker": "NOX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973209",
  "id": "02973209",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250728",
  "time": "0939",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m6dws8rvfdfz.pdf",
  "summary": "- **Clinical Trial Update**:  \n  - First cohort for SOF-SKN\u2122 (lowest dose) completed with no safety issues.  \n  - Proceeding to next cohort with higher dose.  \n  - Focus remains on safety, tolerability, and dose escalation.  \n\n- **Market Opportunity**:  \n  - SOF-SKN\u2122 targets autoimmune diseases (e.g., cutaneous lupus erythematosus) with a global market >US$3.3B.  \n  - Potential expansion to psoriasis, dermatomyositis, and other immune-related diseases.  \n\n- **Pipeline Potential**:  \n  - Sofra\u2122 platform has broad applications (autoimmunity, inflammation, oncology).  \n  - Autoimmune therapeutics market projected to reach US$219.6B by 2035.  \n\n*No capital markets or trading-specific actions identified (e.g., no capital raising, material financials, or timetable events disclosed).*",
  "usage": {
    "prompt_tokens": 1705,
    "completion_tokens": 188,
    "total_tokens": 1893,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-27T23:57:11.390191"
}